The Swiss Group for Clinical Cancer Research (SAKK) has provided groundbreaking insights into the effect of aspirin in colorectal cancer patients with PIK3CA mutations with the SAKK 41/13 Trial.

Under the direction of Prof. Dr. med. Ueli Gueller, of Spital STS AG, the international trial showed that daily aspirin use can reduce the risk of relapse by 43%. The trial was conducted in 55 hospitals in four countries and has now been published in the renowned journal Clinical Cancer Research. The results were presented at the ESMO Congress in September 2024 and attracted great interest among experts.

Special thanks go to all the investigators and researchers involved, in particular Prof. Ueli Gueller MHS, MD, Prof. Markus Joerger, MD, PhD, and SAKK statistician Dr. Stefanie Hayoz, whose commitment and expertise have made this important study possible.

Publication

Press Release 09/24